Awakn Partners With University Of Nottingham For Preclinical Testing Of Psychoactive Therapy
Portfolio Pulse from Juan Spínelli
Awakn Life Sciences Corp. (OTC:AWKNF) has partnered with the University of Nottingham for preclinical testing of its aminoindane compound, aimed at treating trauma-related mental health disorders like PTSD. The study will use rodent models to assess the compound's efficacy, with results expected by the end of 2024.
October 15, 2024 | 5:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Awakn Life Sciences has partnered with the University of Nottingham for preclinical testing of its aminoindane compound, which could revolutionize treatment for PTSD and other trauma-related disorders.
The partnership with a reputable institution like the University of Nottingham for preclinical testing is a positive development for Awakn Life Sciences. It indicates progress in their R&D pipeline and potential future success in treating PTSD, which could positively impact the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100